ArticleCancer pathogenesis and therapy2026
Efficacy and safety of SCT200 in patients with recurrent or metastatic head and neck squamous cell carcinoma after platinum failure: A phase 2 study.
Article in Cancer pathogenesis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03713372 (A Study of Evaluating Recombinant Human Anti-EGFR Monoclonal Antibody), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of Evaluating Recombinant Human Anti-EGFR Monoclonal Antibody (SCT200) for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma After Failure of Platinum-based Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are limited treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing after platinum-based therapy. Epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies (mAbs) have demonstrated efficacy in R/M HNSCC. This phase 2 study evaluated the efficacy and safety of SCT200, a novel fully humanized EGFR mAb, in Chinese patients with R/M HNSCC progressing after platinum-based therapy. Methods: This was a single-arm, multi-center phase 2 study, which enrolled patients with R/M HNSCC who had progressed after ≥2 cycles of platinum-based therapy. All patients received SCT200 at 6.0 mg/kg weekly for the first 6 weeks, followed by 8.0 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was the objective response rate (ORR). Results: Between November 14, 2018, and April 2, 2020, 36 patients were enrolled. The ORR was 13.9% (5/36, 95% confidence interval [CI]: 4.7-29.5), the complete response rate was 2.8% (1/36), while the partial response rate was 11.1% (4/36). The disease control rate was 69.4% (25/36, 95% CI: 51.9-83.7). The median time to response was 1.38 months (95% CI: 0.99-2.60). The median duration of response was 5.95 months (95% CI: 2.60-not reached [NR]). The median progression-free survival and overall survival were 3.98 months (95% CI: 2.76-5.32) and 8.77 months (95% CI: 6.64-NR), respectively. Grade ≥3 treatment-related adverse events occurred in 44.4% (16/36) of patients, with the most common being hypomagnesemia (7/36, 19.4%, 95% CI: 8.2-36.0), hypokalemia (3/36, 8.3%, 95% CI: 1.8-22.5), rash (2/36, 5.6%, 95% CI: 0.7-18.7), and anemia (2/36, 5.6%, 95% CI: 0.7-18.7). Conclusions: This study demonstrated promising efficacy and a manageable safety profile of SCT200 in patients with R/M HNSCC progressing after platinum-based chemotherapy. Trial registration: Clinical Trials.gov, NCT03713372; https://www.clinicaltrials.gov.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.